Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population
- DOI
- 10.1186/s10194-024-01727-0
- Published
- 2024-02-12
- Container
- The Journal of Headache and Pain
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s10194-024-01727-0,
title = {Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population},
author = {Carlos Lazaro-Hernandez and Edoardo Caronna and Joana Rosell-Mirmi and Victor J Gallardo and Alicia Alpuente and Marta Torres-Ferrus and Patricia Pozo-Rosich},
year = {2024},
journal = {The Journal of Headache and Pain},
doi = {10.1186/s10194-024-01727-0},
url = {https://doi.org/10.1186/s10194-024-01727-0}
}RIS
TY - JOUR TI - Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population AU - Carlos Lazaro-Hernandez AU - Edoardo Caronna AU - Joana Rosell-Mirmi AU - Victor J Gallardo AU - Alicia Alpuente AU - Marta Torres-Ferrus AU - Patricia Pozo-Rosich PY - 2024 JO - The Journal of Headache and Pain DO - 10.1186/s10194-024-01727-0 UR - https://doi.org/10.1186/s10194-024-01727-0 ER -
APA
Lazaro-Hernandez, C., Caronna, E., Rosell-Mirmi, J., Gallardo, V. J., Alpuente, A., Torres-Ferrus, M., & Pozo-Rosich, P. (2024). Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-024-01727-0
Source records
- crossref · retrieved 2026-09-25T12:13:44.108Z